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Abstract
This review is focused in PI3K’s involvement in two widespread mental disorders: Autism and Schizophrenia. A large
body of evidence points to synaptic dysfunction as a cause of these diseases, either during the initial phases of
brain synaptic circuit’s development or later modulating synaptic function and plasticity. Autism related disorders
and Schizophrenia are complex genetic conditions in which the identification of gene markers has proved difficult,
although the existence of single-gene mutations with a high prevalence in both diseases offers insight into the role
of the PI3K signaling pathway. In the brain, components of the PI3K pathway regulate synaptic formation and plasticity;
thus, disruption of this pathway leads to synapse dysfunction and pathological behaviors. Here, we recapitulate recent
evidences that demonstrate the imbalance of several PI3K elements as leading causes of Autism and Schizophrenia,
together with the plausible new pharmacological paths targeting this signaling pathway.
PI3K signaling pathway and neurological diseases
Background
The phosphoinositide 3-kinase (PI3K) signaling is one of
the pathways controlling cell survival, proliferation and
apoptosis. Mutations on this pathway are often found in
cancer cells, favoring tumor cell survival and spreading
[1]. When appearing in neuronal tissue, similar muta-
tions result in a different phenotype affecting neuronal
morphology and synaptic transmission and, in some
cases, severe learning and behavioral imbalances [2]. For
instance, mutations in PTEN, neurofibromatosis (NF1)
or in the tuberous sclerosis complex, cause an overacti-
vation of the PI3K/Akt/mTOR pathway, leading to
autism-related behavior, tuberous sclerosis and macro-
cephaly [3, 4]. Furthermore, Fragile X syndrome (FXS), a
common inherited form of mental retardation and the
leading cause of autism, has been associated with over-
activation of the PI3K-mTOR pathway [5]. The opposite
is also true; low levels of PI3K/Akt/mTOR activity are
linked with Rett syndrome (RTT), a rare case of autism-
associated disease [6].
Altered PI3K signaling pathway has also been associated
with schizophrenia [7–9]. Genetic susceptibility factors
such as Neuregulin-1 (NRG1) and its receptor ErbB4,
Disrupted-in-Schizophrenia-1 (DISC1) and Dysbindin-1,
regulate PI3K/Akt signaling [9, 10]. The NRG1 receptor
ERBB4 exists in different isoforms depending on its extra-
cellular juxtamembrane domain or C-terminal cytoplas-
mic tail (CYT) [11]. The CYT-1 isoform of Erb4 contains
a PI3K binding site that activates PI3K signaling [8, 12].
Hence, deregulation of the NRG1/Erb4/PI3K pathway
leads to increased levels of CYT-1 and of the catalytic
PI3K subunit p110δ (PIK3CD) [8]. NRG1 also regulates
DISC1 expression, and it is required for DISC1 mainten-
ance during cortical development. The mechanism is me-
diated via ErbB2/3 receptors and PI3K/Akt signaling [13].
A paralog of NRG1, Neuregulin-3 (NRG3) is another risk
factor associated with schizophrenia [14, 15]. Interestingly,
recent findings have revealed that the molecular ma-
chinery underlying NRG3 overexposure involves Akt
signaling [15].
AKT1 is considered to be a potentially susceptible
gene for the development of schizophrenia. Accordingly,
impairment of AKT1/GSK3β signaling in this disorder
has been clearly demonstrated [16–18]. The levels of
AKT1 are reduced in the prefrontal cortex and the
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hippocampus of postmortem brains, as well as in the
peripheral lymphocytes of individuals with schizophrenia
[18]. A disturbance in growth factors also seems to con-
tribute to an aberrant PI3K/Akt pathway and the patho-
genesis of the disease [9].
Synaptic dysfunction is a common hallmark in ASD
and Schizophrenia. Interestingly, during the last decade
it has been increasingly highlighted the role of PI3K sig-
naling in the modulation of synaptic plasticity [19–22].
Thus, a relationship between altered PI3K pathway and
synapse pathology may be established.
In this article, we give an overview of some well-
characterized mutations in several elements of the PI3K
molecular cascade and their importance in autism and
schizophrenia.
PI3K-Akt signaling pathway
PI3K, first discovered by Lewis Cantley and colleagues
[23, 24], constitutes a family of intracellular lipid kinases
that phosphorylate the 3-OH of the inositol ring of phos-
phatidylinositols (PtdIns) at the plasma membrane lipids.
Three classes of PI3Ks can be found in mammals, and all
three are expressed in the mammalian central nervous
system. Class I comprises p110α (PIK3CA), p110β
(PIK3CB), p110γ (PIK3CG) and p110δ (PIK3CD) and it is
further divided into IA and IB. IA includes the p110α,
p110β and p110δ that bind the p85 regulatory subunit
(PI3KR1), while Class IB consists of p110γ [25]. Class II
includes three different types, C2α, C2β and C2γ. Finally,
there is PI3K-C3, the only member of the ubiquitously
expressed Class III, also named vacuolar protein sorting
34 (Vps34) [26, 27]. Class I, perhaps the best-studied and
characterized, is a heterodimer composed of one regula-
tory (p85) and one catalytic subunit (p110). Class I activa-
tion might rely on a tyrosine kinase receptor (IGF-1, EGF)
or on a G-protein coupled receptor, such as the metabo-
tropic glutamate receptors. However, full p110 catalytic
activity requires Ras activation through a Ras-interacting
domain present in the p110 sequence [28, 29]. Upon acti-
vation, the regulatory subunit interacts with the catalytic
subunit through a Src-homology domain 2 (SH2), pro-
moting a conformational change that activates the cata-
lytic subunit, inducing a local increase in PtdIns [3–5]P3
at the membrane level, that can subsequently function as
an attractor of proteins with a pleckstrin domain, such are
Akt (also known as PKB) or PDK1 (Phosphoinositide-
dependent kinase-1) (Fig. 1).
Akt is the major downstream effector of PI3K, upon
membrane docking and in order to be functional, Akt
needs to be phosphorylated by two kinases: PDK1 and
mTORC2. Downstream Akt lies the TSC1/TSC2 com-
plex (Tuberous Sclerosis Complex1/2) that constitutively
represses mTORC1 activity. TSC1 stabilizes TSC2. TSC2
has a GTPase-activated protein (GAP) domain that
stimulates the GTPase activity of the small GTPase Rheb
(Ras Homolog Enriched in Brain). Akt activation induces
TSC2 phosphorylation and consequently inactivation
of the complex due to the disruption of its GTPase
function. The resulting GTP-bound Rheb promotes
mTORC1 activity (mammalian target of rapamycin 1).
Thus, direct phosphorylation of TSC2 by Akt inhibits its
functions, and therefore mTORC1 activation (Fig. 1).
Mutations in the tumor suppressor genes encoding
TSC1 (Hamartin) and TSC2 (Tuberin) lead to a multi-
systemic tumor syndrome called tuberous sclerosis,
which is characterized by neoplastic lesions (i.e., hamar-
tomas) [30].
PI3K actions are antagonized by PTEN (phosphatase
and tensin homolog deleted on chromosome 10). PTEN,
which was originally cloned as a tumor suppressor
protein, dephosphorylates PtdIns(3–5)P3 to generate
PtdIns(4, 5)P2 [31]. PTEN is one of the most frequently
mutated proteins found in tumor cells. Null mice for
PTEN die during embryogenesis. Interestingly, germline
PTEN mutans cause autosomal dominant hamartomas,
mental retardation, and in some cases, macrocephaly
[32, 33].
Autism and related disorders as a synaptic dysfunction
Autism comprises a group of disorders that are collectively
termed as autism spectrum disorders (ASD). These disor-
ders share similar clinical features including impaired
social behavior and language skills, limited range of inter-
ests and the exhibition of ritualistic and repetitive behav-
iors [34]. Recent data indicate that the prevalence of ASD
is close to 1.1 % [35]. Cognitive impairment and mental
retardation are common attributes of autism (70 %),
accompanied by minor and inconstant abnormalities in
brain morphology. However, it should be noted that a
conspicuous 10 % of ASD patients suffer from macroceph-
aly [36, 37]. Intriguingly, 10 % of autistic patients show an
extraordinary talent, and are often referred to as idiot
savants [38].
A large body of evidence points to synaptic dysfunc-
tion as a cause of the disease [39]. First, most of the be-
havioral and cognitive disorders become evident prior to
3 years of age, a period characterized by intense synaptic
remodeling in the human brain [40]. Second, several
ASD-related mutations have been identified in synaptic
proteins including Shank3, Homer or PSD95 scaffolds
[41]. Third, mutations in the synaptic adhesion mole-
cules neuroligins (NLGS), which control the balance be-
tween excitatory and inhibitory neurotransmission in
mammalian brains, are associated with ASD [42, 43].
NLGS mutations represent less than 1 % of genetic
ASD; however mutations of NLGS receptors, such as
NRXN1 (Neurexin-1-alpha gene) and CNTNAP2 (Con-
tactin-associated protein-like 2) have been identified in
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ASD patients [44–46]. Finally, a high percentage of ASD
patients (10–30 %) also suffer from epilepsy [47].
Early genetic studies employing twins suggested that
ASD has a genetic origin [48]. More recent studies
have estimated that the inheritance of ASD is close to
a 50 % [49], although due to the polygenic origin of
the disease, the genetic causes have been elusive [50].
Only 8–15 % of all cases of ASD are associated with
a mutation located in a single gene, and remarkably,
more than half of these mutations are directly or in-
directly related to the PI3K/Akt/mTOR pathway. In-
directly supporting the imbalance of PI3K and its
relation with autism, some groups have reported a re-
duction of IGF-1 levels in the cerebrospinal fluid of
autistic children [51] and low levels of phospho-Akt
in the brain of autistic subjects [52].
PI3K signaling pathway-associated mutations in ASD
P110-Akt
As previously mentioned, macrocephaly is a recurrent
theme in ASD patients. ASD children born with normal
brain size, but during the first six years of life, the circum-
ference of the head undergoes abnormal growth. Although
the nature of brain overgrowth is not well understood, the
presence of too many neurons, dendrites, spines or even
glial cells could explain this clinical feature. Somatic muta-
tions of the catalytic subunit p110α induce megalencepha-
lies and hemimegalencephalies (HME) as well as brain
Fig. 1 PI3K signaling and common mutations related with ASD and schizophrenia. Class I PI3K is activated by growth factors through a tyrosin
kinase receptor. The PI3K activation results in the conversion of PtdIns [4, 5]P2 (PIP2) to PtdIns [3–5]P3 (PIP3), a process that is reversed by the
action of PTEN. PIP3 serves as docking for Akt and PDK1. Akt, indirectly, stimulates mTORC1 resulting in an augment of protein synthesis by
phosphorylation of the ribosomal kinase p70S6K or 4E-BPs. Phosphorilation of the former releases its binding to eIF4E and enhances translation.
The mTOR kinase is encoded by a single gene in mammals, but it is the active enzyme in two multi-protein complexes called mTORC1 and 2.
mTORC1 is defined by the Raptor subunit (regulatory-associated protein of mTOR) while mTORC2 by the Rictor (rapamycin-insensitive companion
of mTOR). mTORC2 is also activated by growth factors through a not well-defined PI3K-dependent mechanism. mTORC2 contributes to the full
activation of Akt by phosphorylation on serine 473 (for a review see [156]). An important kinase downstream of PI3K is GSK3, which is inhibited
by direct Akt phosphorylation. Among other functions GSK3 regulates TSC activity and indirectly protein translation. Several signaling pathways
dramatically alter PI3K activity. Downstream mGLUR5, fmr1 regulates transcriptional levels of PIKE or the catalytic PI3K subunit p110β. Mutations in
the phosphatase PTEN enhance mTOR dependent translation. Mutations on NF1 enhance Ras and p110 catalytic
activity. Lack of MecP2 expression reduces BDNF levels that in turn contributes to a general deficit of PI3K signaling. Mutations in the PI3K catalytic subunit
p110δ or Akt3 isoform are associated with schizophrenia. Elevated levels of CYT-1 expression, one of the isoforms of the ErbB4 receptor, raised expression
of the p110δ subunit and are also connected with schizophrenia
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malformations characterized by an overgrowth of either
or both of the cerebral hemispheres (HME; 18 % in a co-
hort of 33 affected children [53]). HME, in addition, are
often associated with developmental delays and epilepsy
[54, 55]. Another element of the PI3K pathway found in
somatic mutations of HME patients is the Akt3 brain kin-
ase isoform. Activating mutations or genomic duplications
encoding Akt3 were found in three of eight brain resec-
tions from patients with HME [54, 56]. Accordingly, the
PDK1-K465E knock-in mice, that express a PDK1 muta-
tion with an impaired membrane phosphoinositides inter-
action, shows low levels of Akt activation and a reduced
brain size [57].
PTEN
Loss of function in the negative regulator PTEN has
been linked to macrocephaly and ASD. Mutations in
PTEN gene have been found in 5 % of ASD patients
with macrocephaly [33] and recent studies focused on
pediatric patients with ASD found a mutation preva-
lence rate of 7–8.3 % [58, 59]. Additionally, subjects with
developmental delay/mental retardation have a higher
prevalence (12.2 %) of PTEN mutations [58]. Work in
animal models has revealed that PTEN null mutant mice
exhibit embryonic lethality, while the heterozygotes are
highly susceptible to tumors [60]. Mammalian primary
neuron cultures and Drosophila null mutants of PTEN
show extensive dendritic arborization, which highlights
the role of the PI3K/AKT/mTOR pathway in the regula-
tion of neuronal growth [61, 62]. Accordingly with the
relationship between neuronal overgrowth and ASD,
brain-specific conditional PTEN null mice develop den-
dritic hypertrophy, increased spine density and progres-
sive macrocephaly confined to the affected brain areas.
Interestedly, PTEN mutant mice display abnormal social
interactions that resemble autism-like behaviors [63, 64].
The abnormal morphology was associated with Akt
hyperactivity and overactivation of mTORC1 and its
downstream element p70S6K [64]. Chronic treatment
with rapamycin (mTORC1 inhibitor) reverted the
PTEN-mutant phenotype, suggesting that inhibition of
mTORC1 could be a pharmacological target in the treat-
ment of ASD. Interestingly, rapamycin treatment amelio-
rates the social deficits in the inbred mouse strain BTBR,
a non-syndromic model of ASD [65].
Tuberous sclerosis and TSC1/TSC2 complex
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant disorder caused by mutations in Hamartin or
Tuberin genes [66]. The estimated prevalence of TSC is
6.8–12 per 100 000 persons, with no sex or ethnic differ-
ences. The estimated incidence of tuberous sclerosis at
birth is one in 5800 newborns [67]. TSC is a multisystem
syndrome classically associated with the occurrence of
cortical brain dysplasias, called tubers. The effects of
these mutations on the brain are associated with high
susceptibility to ASD and macrocephaly. Between 25 %
and 61 % of individuals affected by TSC meet the diag-
nostic criteria for autism [68], and 50 % of those with
TSC have some type of learning disability [69].
Conversely, mutations in TSC1/2 appear in 1–4 % of all
cases of autism [3]. Similar to PTEN mutations, inhibi-
tory mutations in any of the TSC elements of the com-
plex would result in an imbalance in mTORC1 activity,
increasing protein translation and modifying neuronal
morphology [30, 70]. Mutant flies from the gigas gene, a
fly orthologue of TSC2, have changes on cell size. Inter-
estingly, gigas neurons increase two-fold the number of
synapses established with their target neurons [71]. In
the other hand, mice with heterozygous mutations in
TSC2 show cognitive deficits similar to human TSC
patients. In this mouse model, treatment with rapamycin
compensates for deficits in context discrimination and
spatial memory [72].
PI3K signaling in Neurofibromatosis type 1 and RASopathies
Ras/mitogen activated-protein kinase (MAPK) and PI3K/
Akt pathways are two signaling cascades with a high de-
gree of cross-regulation among their elements [73].
Remarkably, both pathways have been reported to coordi-
nately mediate neuronal survival and axonal growth [74]
and to independently or synergistically modulate dendritic
arbor and spine morphogenesis [75]. Furthermore, Ras/
MAPK and PI3K/Akt pathways are also required for
proper neuronal migration during cortical development
[76]. Mutations in the genes that encode components of
the RAS/ MAPK pathway lead to a special class of disor-
ders commonly referred as RASopathies [77]. This family
includes, among others, Noonan syndrome, Costello syn-
drome or Neurofibromatosis type 1 (NF1). The latter is a
familial cancer syndrome caused by an autosomal domin-
ant mutation of NF1 gene, affecting 1/3000-5000 individ-
uals worldwide. NF1 patients suffer from Schwann cells
tumor cell affecting peripheral nervous system (neuro-
fibromas) or astrocytomas [78, 79]. In NF1, a mutation
disrupts neurofibromin, a GTPase that negatively regu-
lates p21Ras, resulting in an enhancement of Ras activity
and upregulation of PI3K [79, 80]. As mentioned, Ras
binds directly to p110 catalytic subunit, further modulat-
ing its activity [81, 82]. NF1 children are often afflicted
with cognitive and social deficits that resemble ASD [83].
A recent study estimates that in the U.K. a total of 29.5 %
of NF1 patients were diagnosed with severe ASD whereas
27.7 % with a moderate ASD [84]. Linking NF1 to the
process of synaptic regulation, 6.5 % of NF1 patients had
documented epilepsy [85]. Interestingly, mice that are
heterozygous for the NF1 gene have deficits in visual
attention, spatial learning and hippocampal long-term
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potentiation (LTP). Treatment with lovastatin, a farnesyl
transferase inhibitor that blocks Ras membrane attach-
ment, reverses mutation effects [86].
Deregulation of PI3K signaling in the Fragile X syndrome
FXS syndrome provides evidence that mutations of dis-
tant regulatory elements of the PI3K pathway also cause
ASD. FXS is an X-linked form of mental retardation that
occurs by the loss of function of the X-fragile mental re-
tardation protein (fmr1 [87]). The exact number of
people who have FXS is unknown, but it has been esti-
mated that human prevalence is about 1 in 4000 for
males and 1 in 6000 for females [88]. FXS is the most
common form of inheritable intellectual disability and a
genetic leading cause of autism. Indeed, around 15–30 %
of FXS patients develop ASD and conversely a 5 % of di-
agnosed autistic children are found to have FXS. At the
molecular level, fmr1 is a translation regulatory element
that binds to hundreds of specific mRNAs, repressing
their translation (more than 400 have been identified
[89]). In humans, FXS results from the expansion of a
CGG repeat sequence in the 5′ untranslated region of
fmr1, which induces a functional silencing of the gene
(5–20 in normal person and more than 200 in affected
[90]). The lack of fmr1 causes a broad deregulation of
translation, as evidenced by a substantial 20 % increase
in the rate of brain protein translation in the FMR1
knockout mice (KO) [91, 92]. Neuroimaging studies of
human patients have revealed some morphological brain
anomalies, including increased brain size, larger amyg-
dala and hippocampus, as well as ventricular abnormal-
ities, among others [93, 94].
Two prominent features of FXS found in both humans
and mouse models are the presence of aberrant dendritic
spines and an exaggerated form of Long Term Depres-
sion (LTD [95]). The so called “mGluR theory of FXS”
postulates that excessive protein synthesis downstream
from gp1 mGluRs (group one of glutamate metabotropic
receptors) underlies most of the FXS symptoms [96].
Supporting this hypothesis, both genetic and pharmaco-
logical targeting of mGluR alleviates FXS manifestations
[97, 98]. Therefore, in rodent models, allosteric antago-
nists of mGluR5 (such as MPEP or AFQ056) have dem-
onstrated a degree of efficiency in both reverting LTD,
aberrant spines and ameliorating some of the behavioral
defects [98, 99].
The altered elements downstream of mGLuRs are still a
matter of study, but numerous components of the PI3K/
Akt/mTOR pathway appear to be clearly upregulated in the
absence of functional fmr1 expression. Experimental evi-
dence confirms this point: FMR1 KO mice show elevated
levels of phospho-Akt, phospho-mTOR and phospho-
p70S6, as well as excessive mTOR cap-dependent transla-
tion and deregulated LTD [5, 96, 100–102]. Even human
postmortem tissue shows altered mTOR signaling evi-
denced by enhanced phosphorylation of Akt levels (up-
stream mTOR regulator) and S6K1 (downstream mTOR
substrate) [103]. Conversely, inhibition of protein synthesis
with mTORC1 inhibitors such rapamycin or temsirolimus,
reduces basal protein synthesis and ameliorates cognitive
deficit, measured by the object recognition test, as well as
susceptibility to audiogenic seizures [104].
Levels of PIKE (PI3K enhancer), an upstream activator
of mTOR and an identified mRNA target of FMR1, are
elevated in FMR1 KO mice. PIKE should link mGluR ac-
tivity with PI3K signaling; nonetheless, it has been sug-
gested that this upregulation underlies the high content
of mTOR-dependent translation found in FXS synapses
[101]. PIKE is not the only element of the PI3K pathway
upregulated in FXS neurons; p110β, the catalytic isoform
of PI3K Class I is augmented in mouse neurons deficient
in Fmr1 and in lymphoblastoid cells from FXS patients,
causing excessive protein synthesis [5, 105]. Specific in-
hibitors of the p110β subunits, such as TGX221, restore
normal protein synthesis in cortical synaptosomes of
FMR1 KO mice and reduce Akt activity in the lympho-
cytes of human patients, without affecting wild type cells
[105]. Alternatively, altered PI3K/Akt/mTOR may not
be the cause, rather the consequence of the lack of fmr1
activity, nevertheless, elements downstream mGluR acti-
vation appears to be promising pharmacological targets
in FXS.
A particular case of PI3K signaling imbalance: Rett syndrome
Rett syndrome (RTT) is a monogenic X-linked disease
with a prevalence of 0.4 per 10000 females [106]. RTT
shares a high co-morbidity with ASD, it develops during
the first 6–18 months of life, and its clinical features in-
clude progressive mental decline, autism and stereotyped
movements. Notably and different from ASD, patients
suffer from a severe deregulation of the motor and sen-
sory system and an important disturbance of the autono-
mous nervous systems, producing an irregular heart rate
and breathing patterns that will eventually result in the
death of the patient. At the histological level, RTT is
characterized by a series of features that include a reduc-
tion of cortical thickness, decreased volume of neurons,
fewer dendritic branches and poor development of
spines.
The syndrome is mainly caused (90 %) by a mutation
in the methyl-CpG-binding protein2 gene (MeCP2
[107]). MeCp2 is ubiquitously expressed, although the
brain displays the highest levels of expression [108], with
similar amounts of expression in both neurons and
astrocytes [109].
MeCp2 is a methylation binding protein that selectively
binds to specific DNA regions, inhibiting transcription
[107, 110]. It has thus been hypothesized that MeCp2 is a
Enriquez-Barreto and Morales Molecular and Cellular Therapies  (2016) 4:2 Page 5 of 12
chromatin-silencing regulator [111]. Recently, a more
complex picture has emerged, because MeCp2 can act as
a transcriptional activator through the cAMP-Response
Element Binding protein (CREB), and as a RNA-splicing
modulator, regulating the expression of miR-132/212, both
of which are known to affect visual cortical plasticity and
ocular dominance [112]. MeCP2 indirectly modifies the
activation level of PI3K by regulating the transcription of
IGF-1 and BDNF. In this way, MeCp2 participates in a
complex and not well-understood regulatory cycle that in-
volving miR-132/212 and CREB, modulates IGF1 and
BDNF expression, which in turn activates PI3K [113, 114].
In humans, MeCp2 mutant embryonic stem cells dis-
play low levels of p-Akt and p-S6, and overall reduced
transcription and translation levels [115]. Similarly, the
brains of MeCp2 knockout mice show reduced levels of
p-Akt and two markers of protein synthesis, such as
Rack1 and eIF6 [116, 117]. BDNF expression is reduced
in knockout MeCp2 mice [118, 119] and in human pa-
tients [120]. Conversely, restoring BDNF activity im-
proves physiological functions and survival. Thus, in
RTT mice models, treatments with promoters of BDNF
synthesis, such as sphingosine or a druggable intercellu-
lar loop of the TrkB receptor, improve locomotor activity
and survival in MepC2 deficient mice [121, 122]. The
pharmacological target of IGF-1 also ameliorates Rett
symptoms, while treatment of MeCp2-deficient mice
with an active fragment of IGF-1 increases their life
span, improves locomotor functions, ameliorates breath-
ing patterns and normalizes the heart rate [123]. Similar
results were obtained by injecting recombinant human
IGF-1 in a mouse model, which improved respiratory
patterns, reduced anxiety and increased exploratory be-
havior. Augmented levels of phosphorylated Akt were
found in cortical homogenates of MeCp2-deficient mice
after treatment, an effect that parallels the augmented
PSD95 synaptic amounts observed in these animals
[124]. More recently, findings from the same group have
demonstrated the effects of mecarsermin (a druggable
recombinant human IGF-1) in human patients. The re-
sults of a short-term treatment consisting of a daily dose
administered for 4 weeks showed that the use of IGF-1
is safe and it ameliorates irregular breathing and anxiety,
although it did not improve intellectual disabilities.
Nonetheless, this result clearly paves the way for the
use of the PI3K activators in the treatment of Rett
syndrome [125].
Impaired PI3K signaling in schizophrenia
Schizophrenia is a severe psychiatric disorder affecting ap-
proximately 1 % of the population worldwide [126]. It is
characterized by symptoms such as hallucinations, delu-
sions, apathy and social withdrawal, reduced motivation,
disorganized communication and cognitive impairments
[127–129]. Clinical symptoms of schizophrenia are usually
manifested during adolescence and early adulthood [126],
although at present, seminal evidence supports the idea
that schizophrenia has a neurodevelopmental origin [130].
PI3K
Dysfunction in the PI3K signaling pathway has been con-
nected with the pathogenesis of schizophrenia [7, 8, 10].
Accordingly, family-based association studies of schizo-
phrenia have revealed PI3K class 3 (PIK3C3) genetic con-
tributions to the pathogenesis of the disorder [131].
Genetic analysis of the promoter region of PIK3C3 in pa-
tients with schizophrenia pointed to a mutation that prob-
ably results in diminished gene transcription [132]. Other
studies of gene expression patterns in peripheral blood
leucocytes of schizophrenic individuals evidenced a de-
crease in the expression of the PI3K catalytic subunit-α
(P110α, PIK3CA) [133].
Two susceptibility factors for schizophrenia, NRG1
and DISC1, have been demonstrated to be linked by a
common pathway involving PI3K/Akt. It is interesting to
note that animal models of NRG1 and DISC1 exhibit
similar phenotypes, such as impaired prepulse inhibition
and working memory deficits. These similarities can be
now explained in terms of the ability of NRG1 to medi-
ate DISC1 expression via ErbB2/3 and PI3K/Akt signal-
ing [13]. Furthermore, a risk pathway has been recently
reported in schizophrenia that involves NRG1, the ErbB4
receptor isoform CYT-1 and the p110δ catalytic subunit
of the IA PI3K class [8]. Thus, in human brains and in
lymphoblastoid B-cell lines (LCLs) of subjects with schizo-
phrenia, an ErbB4 risk haplotype (AGG; rs7598440,
rs839523, rs707284) was found to be associated with ele-
vated ErbB4 CYT-1 transcription and consequently raised
expression of PIK3CD (p110δ). Importantly, despite aug-
mented PIK3CD levels, PI3K signaling is reduced; this sur-
prising result points to a complex deregulation of the
NRG1/ERBB4/PI3K pathway, with a negative effect on the
PI3K signaling in this disease [8, 134]. Law and colleagues
cite similar results regarding elevated levels of PIK3CD,
accompanied by dampened PI3K signaling in neuroblast-
oma tumors [135, 136], an effect suggesting that PIK3CD
may act as a tumor suppressor. Quantitative analysis of
gene transcripts reveals an increased expression of the
catalytic subunit PIK3CD and the regulatory subunit
PIK3R3 (p55γ), although data correlation studies indicate
that PIK3CD is the subunit genetically implicated in this
disorder [8].
Although PIK3CD mRNA expression in the hippo-
campus and prefrontal cortex of normal individuals is
associated with the risk haplotype of ErbB4, this associ-
ation is not observed in schizophrenic subjects in the
hippocampus or the dorsolateral prefrontal cortex, an ef-
fect that could be the consequence of antipsychotic drug
Enriquez-Barreto and Morales Molecular and Cellular Therapies  (2016) 4:2 Page 6 of 12
treatment [8]. Consistent with this hypothesis, haloperi-
dol administration in rats reduced PIK3CD gene expres-
sion in the brain [8]. Such findings by Law and
colleagues indicate that specific inhibition of the
PIK3CD protein (p110δ) may represent a useful ap-
proach for the treatment of schizophrenia. Therefore,
the effect of small molecule IC87114, a compound that
selectively inhibits p110δ catalytic activity, was tested in
a model of amphetamine-induced hyperlocomotion in
rodents. Its antipsychotic potential was confirmed as a
result of a dramatic blockade of the amphetamine-
induced hyperlocomotion. Contrary to hypokinesia caused
by antipsychotic drugs, the administered dose of IC87114
had no effect on the spontaneous locomotor activity in the
absence of amphetamine [8]. The IC87114 compound was
also found to modulate Akt activity in mice by significantly
increasing Akt phosphorylation levels on Thr308, thus con-
firming the specific action of IC87114 on the PI3K signaling
pathway [8]. The therapeutic potential of IC87114 was also
addressed in a model of rat neonatal ventral hippocampal
lesion (NVHL), a neurodevelopmental animal model of
schizophrenia. These animals exhibit altered prepulse
inhibition (PPI) of the acoustic startle response.
IC87114 treatment induced a highly significant im-
provement of PPI in these rats, as compared to sham-
operated animals. In general, the effects of IC87114
seem to be specific to the p110δ catalytic subunit and
present no side effects [8]. Altogether, the data confirm
that p110δ selective inhibition has a promising anti-
psychotic potential.
Neuregulin 3 (NRG3), a paralog of NRG1, is a mol-
ecule of increasing interest, due to its link to psychiatric
disorders that includes schizophrenia. Accordingly, ele-
vated NRG3 expression in the prefrontal cortex of
schizophrenic subjects has been described [14]. In a set
of experiments, an NRG3 EGF peptide consisting of the
EGF domain of human NRG3 was administered during
a critical neurodevelopmental period in mice. The effect
of the treatment produced anxiety-like behavior and
reduced sociability in adulthood, thus demonstrating
that overexposure to NRG3 in early postnatal life has a
negative impact on brain development. The viability of
the peripherally injected peptide indicated activation of
its ErbB4 receptor and Akt signaling in a way similar to
NRG1 [15], confirming the involvement of the PI3K
pathway.
Akt
Dopamine D2 receptors (D2Rs) have been classically con-
sidered as the principal target of antipsychotic drugs
[137]. Schizophrenic subjects present high levels of D2Rs
in the basal ganglia [137], and the sensitivity of postsynap-
tic D2Rs is enhanced in this disorder [137, 138]. Anti-
psychotic drugs can be grouped into two categories,
namely typical and atypical. Both groups of drugs are able
to modify Akt signaling in schizophrenia [9, 137]. In fact,
Akt plays a role in the pathogenesis of the disease. The as-
sociations between schizophrenia and AKT1 genetic vari-
ants have been well established [16, 139, 140], and
decreased levels of Akt1 and substrate phosphorylation
have been reported in the brain of individuals suffering
from the disorder [16, 17].
Lymphocyte-derived cell lines from schizophrenic sub-
jects exhibit reduced levels of Akt [16]. Analysis of post-
mortem brains confirmed lower amounts of Akt1 in the
frontal cortex and the hippocampus [16]. Phosphoryl-
ation of GSK3β at Ser9 in lymphocytes and frontal cor-
tex lysates was also reduced, consistent with a decrease
in Akt1 activity. Sequencing of the AKT1 locus in
schizophrenic individuals revealed an AKT1 haplotype
associated with lower Akt1 protein content [16].
To gain insight into the direct involvement of Akt in
schizophrenia, Emamian and colleagues treated Akt1 −/−
adult mice with amphetamine, a nonselective dopamine
receptor agonist. PPI was then recorded in the mice as a
measure of sensory motor gating. Animals deficient in
Akt1 exhibited a significant reduction of PPI, thus sug-
gesting impairment of the neuronal circuits that gate the
startle reflex. [16] Further analyses were carried out using
intraperitoneal administration of haloperidol, a specific
D2Rs antagonist, in adult C57Bl/6 mice. Haloperidol
usage affected enzymatic Akt activity, and both chronic
and acute treatments modulated Akt phosphorylation
levels. The acute medication produced an increase in
Thr308 phosphorylation; however, chronic administration
augmented the phosphorylation levels at Thr308 and
Ser473, consequently increasing GSK3β at Ser9 phosphor-
ylation [16]. These observations evidenced that anti-
psychotic drugs could compensate for the disruption of
the Akt/GSK3β pathway in schizophrenia.
Some studies indicate that glucose metabolism is
compromised in schizophrenia [141, 142]; hence, de-
tection of the insulin receptor and Akt activity in
postmortem brains of schizophrenic patients, in insu-
lin knockdown HEK cells and in a mouse model of
insulin resistance, revealed a significant reduction in
the number of insulin receptors and in the total and
active forms of Akt. The findings confirm that altered
insulin receptors activity directly impairs insulin/Akt
signaling in this disease [17].
By using Akt1-deficient mice, Lai and colleagues
(2006) studied the effect of Akt1 deficiency on prefrontal
cortex functioning. Thus, transcriptional profiling exam-
ination evidenced changes in the expression of prefrontal
cortex genes involved in actin polymerization, synaptic
transmission, neuronal development and myelination.
Furthermore, changes in dendritic architecture and com-
plexity of prefrontal layer V neurons suggested altered
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neuronal connectivity. Akt1-mutant mice also displayed
abnormal working memory retention [143].
A recent in vitro approach has demonstrated that pali-
peridone, a second-generation antipsychotic, may act as
a neuroprotector. Cultured mouse embryonic prefrontal
cortical neurons were exposed to the NMDA receptor
antagonist MK-801, a compound widely used to model
schizophrenia features in animals. MK-801 notably
affected cell viability in a dose-dependent manner, but
paliperidone effectively prevented neuronal damage.
This protective effect implies Akt/GSK3β activity [144].
Discussion on pharmacological interventions on the PI3K
pathway
ASD and schizophrenia, although etiologically different,
occur with synaptic dysfunction and disruption of neur-
onal networks. Both pathologies have a developmental
origin that might result in synaptic plasticity deficits and
the malfunction of neuronal circuits throughout the sub-
ject’s lifespan. Krueger and Bear [97] have established
three possible scenarios for the treatment of FXS: opti-
mal, pessimistic and hopeful, grading the success of a fu-
ture treatment as a function of the timing and
irreversibility of the impairments [97]. We believe that a
similar scenario could be extended to include ASD and
schizophrenia treatments. A key remaining issue is the
temporal window in which reverting the disease, or if
established, ameliorating the symptoms, is the suitable
choice.
Being optimistic in terms of research progress, we
would like to contribute to the discussion of a hopeful
scenario in which pharmacological treatments can slow
or even reverse the evolution of symptoms in these
neurological disorders. There are two main reasons for
this. First, some of the treatments already tested in
mouse models of ASD have been able to ameliorate both
cognitive and morphological alterations; moreover, a few
clinical tests with humans show promising results (this
is true at least for the use of mGluR5 regulators in FXS
or PI3K activators for Rett syndrome treatment). On the
other hand, most of the cellular mechanisms regulating
neuronal plasticity during development are also present
later in adolescence and adulthood [145, 146].
The neuropathological features of ASD include altered
cellular size and synaptic growth, synaptic plasticity failure,
changes in synaptic proteins, dendritic spine dysmorphol-
ogy and abnormal synaptic homeostasis [3, 147, 148].
Schizophrenia neuropathology comprises ventricular en-
largement, neuron and brain atrophy, reduced dendritic
arborization and hypoplasticity [7]. It is interesting to
consider that the PI3K pathway is involved in neuronal mi-
gration and cortical lamination [149], the regulation of den-
dritic branching [19, 61], synaptogenesis and spinogenesis
[19–21, 150], the control of functional synaptic plasticity
[151, 152] and long-term potentiation in the hippocampus
[153]. Thus, allowing for the spectrum of neurological as-
pects comprised in the pathological conditions here
reviewed, as well as the molecular mechanistic convergence
on PI3K, a promising clinical aim could be the selective tar-
geting of PI3K signaling.
Since mutations in several elements of the PI3K path-
way have been associated with susceptibility to develop
cancer, a large number of clinical trials targeting PI3K
elements are currently underway [154]. Several specific
inhibitors of the p110 catalytic subunit have already been
developed. For instance BYL719 (inhibitor of p110α),
GSK2636771 (inhibitor of p110β) or inhibitors of p110δ
such TGR 1202 are under clinical evaluation for the
treatment of different malignant lymphomas. CAL-101
(also known as idelalisib) has already been approved as
treatment for three types of β cell neoplasm [155]. None
of these drugs has been tested so far for the treatment of
psychiatric or neurodevelopmental disorders. More sur-
prisingly, none of these studies is exploring cognitive
parameters.
In addition to the large number of cancer cell trials
employing rapamycin, the mTOR inhibitor, two clinical
trials are currently focused on the use of this drug to
treat TSC and autism in children. The use of lovastatin
in individuals with NF1 mutations is yet another ex-
ample of crossing pathways for future research; a clinical
Phase I trial is currently concluding, although this study
focuses on safety, not neurophysiologic deficits.
Several clinical studies on treatments for FXS targeting
mGluR have already been completed. Regrettably, a re-
cent Phase II trial employing mGluR5 antagonist mavo-
glurant (AFQ056) has been canceled because the study
did not show a significant improvement of abnormal be-
haviors in adults and adolescents with FXS (source:
www.fraxa.org). Another mGluR5 antagonist (acampro-
sate) is now in clinical trials, studying social impairments
associated with FXS. To date, no clinical study has con-
templated the use of inhibitors/regulators of PI3K path-
way elements for the treatment of ASD.
Probably the most promising field is the treatment of
Rett syndrome. This monogenetic disease has a clear
and well-identified origin and several vegetative dysfunc-
tions that make it easy to monitor progression during
treatment. As previously stated, a clinical Phase I/II
study employing mecaserim has been completed [125],
and a new study also employing human recombinant
IGF-1 is already in the recruiting phase. A second clin-
ical trial (Phase I) is now in its initial phases to study the
safety and tolerance of fingolimod in children with Rett
syndrome.
Nowadays, no clinical trials targeting PI3K elements to
treat Schizophrenia are underway. We hope that the
aforementioned clinical efforts should eventually fuel the
Enriquez-Barreto and Morales Molecular and Cellular Therapies  (2016) 4:2 Page 8 of 12
development of new molecules for the treatment of this
disease based on selective targeting of PI3K elements. In
summary, the studies discussed here open the door to
develop novel therapeutic molecules targeting PI3K-
specific subunits or specific elements of the PI3K/Akt
pathway.
Conclusions
– Unbalance of PI3K signaling is associated with ASD
and Schizophrenia and it may drive synaptic
dysfunction in both disorders
– Pharmacological targeting of PI3K or related
elements could be part of new and promising tools
for ASD and Schizophrenia treatment
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